array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Regeneron Pharmaceuticals Inc" ["slug"]=> string(38) "c469a-us-regeneron-pharmaceuticals-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77" ["description"]=> string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. " ["address_street"]=> string(25) "777 Old Saw Mill River Rd" ["address_place"]=> string(9) "Tarrytown" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1988-02-08" ["website_domain"]=> string(13) "regeneron.com" ["website_url"]=> string(25) "https://www.regeneron.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(10368) ["article_count"]=> int(2748) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(53) "Amgen Launches Its Aflibercept Biosimilar In the U.S." ["snippet_en"]=> string(281) "After the Federal Circuit’s denial last month of Regeneron’s motion for an injunction pending appeal, seeking to prevent Amgen from launching its aflibercept biosimilar, Amgen announced on its Q3 earnings call last week that it has launched its aflibercept biosimilar, PAVBLU." ["url"]=> string(97) "https://www.bigmoleculewatch.com/2024/11/04/amgen-launches-its-aflibercept-biosimilar-in-the-u-s/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/f5eafc47-8794-4445-9c3e-b34794094d71" ["source"]=> string(20) "bigmoleculewatch.com" ["publication_date"]=> string(10) "2024-11-04" ["categories"]=> array(4) { [0]=> string(5) "Legal" [1]=> string(24) "Quarterly/Annual Figures" [2]=> string(14) "Product Launch" [3]=> string(10) "New Market" } } [1]=> array(7) { ["title_en"]=> string(51) "Amgen to launch Eylea biosimilar after court ruling" ["snippet_en"]=> string(260) "Amgen will launch Pavblu, its biosimilar to Regeneron's Eylea, after a US Court of Appeals decision denied Regeneron's request to halt the launch. The ruling allows Amgen to expand access to its treatment despite Regeneron's ongoing patent infringement claims." ["url"]=> string(84) "https://www.aiche.org/news/industry/amgen-launch-eylea-biosimilar-after-court-ruling" ["image_url"]=> NULL ["source"]=> string(9) "aiche.org" ["publication_date"]=> string(10) "2024-11-04" ["categories"]=> array(5) { [0]=> string(10) "Litigation" [1]=> string(5) "Legal" [2]=> string(8) "Verdicts" [3]=> string(14) "Product Launch" [4]=> string(18) "Expansion & Growth" } } [2]=> array(7) { ["title_en"]=> string(131) "[Exclusive] Red flags for global launch of Samsung Bioepis’ ‘Eylea’… Following the US, the UK patent exhibition By The Guru" ["snippet_en"]=> string(368) "[The Guru = Reporter Han Ah-reum] A red flag has been raised regarding the global launch of Samsung Bioepis' macular degeneration treatment 'Eylea' (ingredient name: aflibercept). After losing a patent lawsuit against Regeneron, the original developer of Eylea, in the US in the first half of this year, the company was embroiled in a patent lawsuit in the UK as well." ["url"]=> string(63) "https://kr.investing.com/news/stock-market-news/article-1249121" ["image_url"]=> NULL ["source"]=> string(13) "investing.com" ["publication_date"]=> string(10) "2024-10-31" ["categories"]=> array(4) { [0]=> string(10) "Litigation" [1]=> string(5) "Legal" [2]=> string(21) "Intellectual Property" [3]=> string(5) "Fraud" } } [3]=> array(7) { ["title_en"]=> string(63) "Regeneron loses bid to block Amgen's launch of Eylea biosimilar" ["snippet_en"]=> string(205) "The U.S. Court of Appeals for the Federal Circuit rejected Regeneron's request to block the launch during its appeal of a related decision for Amgen in a patent case in West Virginia, per a Reuters report." ["url"]=> string(82) "https://drugstorenews.com/regeneron-loses-bid-block-amgens-launch-eylea-biosimilar" ["image_url"]=> string(78) "https://images.businessradar.com/articles/030697ee-bdc1-46b8-b3fd-1ea66423331c" ["source"]=> string(17) "drugstorenews.com" ["publication_date"]=> string(10) "2024-10-30" ["categories"]=> array(2) { [0]=> string(10) "Litigation" [1]=> string(5) "Legal" } } [4]=> array(7) { ["title_en"]=> string(107) "Regeneron Stock Price Target Lowered, Outperform Rating Maintained Amid Legal Developments By Investing.com" ["snippet_en"]=> string(90) "Regeneron stock price target lowered, outperform rating maintained amid legal developments" ["url"]=> string(63) "https://ru.investing.com/news/company-news/article-93CH-2542508" ["image_url"]=> NULL ["source"]=> string(13) "investing.com" ["publication_date"]=> string(10) "2024-10-25" ["categories"]=> array(6) { [0]=> string(10) "Litigation" [1]=> string(5) "Legal" [2]=> string(24) "Stock Research & Ratings" [3]=> string(12) "Stock Market" [4]=> string(18) "General Investment" [5]=> string(31) "Financial Update/Profit Warning" } } [5]=> array(7) { ["title_en"]=> string(107) "Amgen Plans At-Risk Launch of EYLEA® Biosimilar Pavblu™ After Federal Circuit Lifts Temporary Injunction" ["snippet_en"]=> string(151) "On October 22, 2024, the Federal Circuit (CAFC Case No. 24-2351) denied Regeneron’s request for an injunction pending appeal for Amgen’s EYLEA®..." ["url"]=> string(80) "https://www.jdsupra.com/legalnews/amgen-plans-at-risk-launch-of-eylea-r-2420962/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/463e3318-d267-4e13-ad2d-00d3bba8336f" ["source"]=> string(11) "jdsupra.com" ["publication_date"]=> string(10) "2024-10-24" ["categories"]=> array(2) { [0]=> string(5) "Legal" [1]=> string(14) "Product Launch" } } [6]=> array(7) { ["title_en"]=> string(78) "Regeneron loses Eylea biosimilar lawsuit... Continuation of the appeal process" ["snippet_en"]=> string(341) "[The Bio Reporter Seong Jae-jun] Regeneron, an American biotechnology company, lost a lawsuit filed to block the launch of a biosimilar of the blockbuster eye treatment Elyea (ingredient aflibercept). Recently, the U.S. Federal Circuit Court Last month, a West Virginia federal court granted Regeneron's request for a preliminary injunction." ["url"]=> string(59) "https://www.thebionews.net/news/articleView.html?idxno=9800" ["image_url"]=> NULL ["source"]=> string(14) "thebionews.net" ["publication_date"]=> string(10) "2024-10-24" ["categories"]=> array(2) { [0]=> string(10) "Litigation" [1]=> string(5) "Legal" } } [7]=> array(7) { ["title_en"]=> string(63) "Regeneron Fails to Block Amgen's Eylea Biosimilar During Appeal" ["snippet_en"]=> string(257) "Regeneron Pharmaceuticals Inc. failed to block Amgen Inc.'s biosimilar of Eylea while it appeals a West Virginia federal judge’s denial of Regeneron’s request for a preliminary injunction, though the Federal Circuit said it will expedite the proceeding." ["url"]=> string(99) "https://news.bloomberglaw.com/ip-law/regeneron-fails-to-block-amgens-eylea-biosimilar-during-appeal" ["image_url"]=> NULL ["source"]=> string(16) "bloomberglaw.com" ["publication_date"]=> string(10) "2024-10-24" ["categories"]=> array(2) { [0]=> string(10) "Litigation" [1]=> string(5) "Legal" } } [8]=> array(7) { ["title_en"]=> string(59) "Legal win leads Amgen to at-risk launch of Eylea biosimilar" ["snippet_en"]=> string(100) "Appeals court lifts injunction on the launch of Amgen's biosimilar of Regeneron's blockbuster Eylea." ["url"]=> string(80) "https://pharmaphorum.com/news/legal-win-leads-amgen-risk-launch-eylea-biosimilar" ["image_url"]=> string(78) "https://images.businessradar.com/articles/ca1e2efe-49c4-42d7-b814-5176f97a44d7" ["source"]=> string(16) "pharmaphorum.com" ["publication_date"]=> string(10) "2024-10-24" ["categories"]=> array(2) { [0]=> string(5) "Legal" [1]=> string(14) "Product Launch" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(263) } [1]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(201) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(196) } [3]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(129) } [4]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(116) } [5]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(116) } [6]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(93) } [7]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(79) } [8]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(67) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(66) } [10]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(61) } [11]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(59) } [12]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(57) } [13]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(56) } [14]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(53) } [15]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(43) } [16]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(40) } [17]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(38) } [18]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(37) } [19]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(37) } [20]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(37) } [21]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(35) } [22]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(33) } [23]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(32) } [24]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(31) } [25]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(28) } [26]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(28) } [27]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(25) } [28]=> array(2) { ["name"]=> string(11) "Sponsorship" ["count"]=> int(21) } [29]=> array(2) { ["name"]=> string(21) "Intellectual Property" ["count"]=> int(20) } } } c469a-us-regeneron-pharmaceuticals-inc

Regeneron Pharmaceuticals Inc

Location

New York

Founded

1988-02-08

Website

https://www.regeneron.com

Articles

2748 Articles

Category

Pharmaceutical Preparations

Description

At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media.

Articles

Amgen Launches Its Aflibercept Biosimilar In the U.S.

2024-11-04 (bigmoleculewatch.com)

Amgen Launches Its Aflibercept Biosimilar In the U.S.

After the Federal Circuit’s denial last month of Regeneron’s motion for an injunction pending appeal, seeking to prevent Amgen from launching its aflibercept biosimilar, Amgen announced on its Q3 earnings call last week that it has launched its aflibercept biosimilar, PAVBLU.

Read more
Amgen to launch Eylea biosimilar after court ruling

2024-11-04 (aiche.org)

Amgen to launch Eylea biosimilar after court ruling

Amgen will launch Pavblu, its biosimilar to Regeneron's Eylea, after a US Court of Appeals decision denied Regeneron's request to halt the launch. The ruling allows Amgen to expand access to its treatment despite Regeneron's ongoing patent infringement claims.

Read more
[Exclusive] Red flags for global launch of Samsung Bioepis’ ‘Eylea’… Following the US, the UK patent exhibition By The Guru

2024-10-31 (investing.com)

[Exclusive] Red flags for global launch of Samsung Bioepis’ ‘Eylea’… Following the US, the UK patent exhibition By The Guru

[The Guru = Reporter Han Ah-reum] A red flag has been raised regarding the global launch of Samsung Bioepis' macular degeneration treatment 'Eylea' (ingredient name: aflibercept). After losing a patent lawsuit against Regeneron, the original developer of Eylea, in the US in the first half of this year, the company was embroiled in a patent lawsuit in the UK as well.

Read more
Regeneron loses bid to block Amgen's launch of Eylea biosimilar

2024-10-30 (drugstorenews.com)

Regeneron loses bid to block Amgen's launch of Eylea biosimilar

The U.S. Court of Appeals for the Federal Circuit rejected Regeneron's request to block the launch during its appeal of a related decision for Amgen in a patent case in West Virginia, per a Reuters report.

Read more
Regeneron Stock Price Target Lowered, Outperform Rating Maintained Amid Legal Developments By Investing.com

2024-10-25 (investing.com)

Regeneron Stock Price Target Lowered, Outperform Rating Maintained Amid Legal Developments By Investing.com

Regeneron stock price target lowered, outperform rating maintained amid legal developments

Read more
Amgen Plans At-Risk Launch of EYLEA® Biosimilar Pavblu™ After Federal Circuit Lifts Temporary Injunction

2024-10-24 (jdsupra.com)

Amgen Plans At-Risk Launch of EYLEA® Biosimilar Pavblu™ After Federal Circuit Lifts Temporary Injunction

On October 22, 2024, the Federal Circuit (CAFC Case No. 24-2351) denied Regeneron’s request for an injunction pending appeal for Amgen’s EYLEA®...

Read more
Regeneron loses Eylea biosimilar lawsuit... Continuation of the appeal process

2024-10-24 (thebionews.net)

Regeneron loses Eylea biosimilar lawsuit... Continuation of the appeal process

[The Bio Reporter Seong Jae-jun] Regeneron, an American biotechnology company, lost a lawsuit filed to block the launch of a biosimilar of the blockbuster eye treatment Elyea (ingredient aflibercept). Recently, the U.S. Federal Circuit Court Last month, a West Virginia federal court granted Regeneron's request for a preliminary injunction.

Read more
Regeneron Fails to Block Amgen's Eylea Biosimilar During Appeal

2024-10-24 (bloomberglaw.com)

Regeneron Fails to Block Amgen's Eylea Biosimilar During Appeal

Regeneron Pharmaceuticals Inc. failed to block Amgen Inc.'s biosimilar of Eylea while it appeals a West Virginia federal judge’s denial of Regeneron’s request for a preliminary injunction, though the Federal Circuit said it will expedite the proceeding.

Read more
Legal win leads Amgen to at-risk launch of Eylea biosimilar

2024-10-24 (pharmaphorum.com)

Legal win leads Amgen to at-risk launch of Eylea biosimilar

Appeals court lifts injunction on the launch of Amgen's biosimilar of Regeneron's blockbuster Eylea.

Read more